2017 IO Featured Talks » Unveiling New Molecular Biomarkers for Immunotherapy Using Immunosequencing



Unveiling New Molecular Biomarkers for Immunotherapy Using Immunosequencing

Catherine Sanders, MT, PhD
Adaptive Biotechnologies

Part 1


Part 2






Catherine Sanders, MT, PhD
Director/Team Lead, Scientific Liaisons
Adaptive Biotechnologies


Catherine M. Sanders is and expert in the field on immunosequencing. She is currently Director/Team Lead, Scientific Liaisons at Adaptive Biotechnologies responsible for establishing partnerships with pharmaceutical companies and collaborations with key opinion leaders in oncology, hematology, transplantation, infectious disease and autoimmunity. She began her career as a post-doctoral fellow at the HudsonAlpha Institute for Biotechnology analyzing immune repertoire changes in cancer, autoimmune disease, and infectious disease. Dr. Sanders received a Ph.D. in immunopathology and a M.S. in pathology from the University of Mississippi Medical Center in Jackson where she focused on TLR, chemokine receptor, and cytokine expression in HIV-infected T lymphocyte subsets. She also holds a BS degree in Medical Technology from Mississippi State University and received her board certification (ASCP) from Vanderbilt University Medical Center.